Pharmaceutical PV DIV - FSB
Ended Awarded
- Contract number
- SPE2DX26FENTX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $16,633
Award facts
- Contract value 100% obligated
- $16,632.54 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $16,632.54 by the Defense Logistics Agency's Medical Supply Chain division on October 29, 2025, with an ultimate completion date of November 3, 2025. This delivery order was issued without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense military healthcare facilities worldwide.
The delivery order authorizes procurement of pharmaceutical products and medical consumables from DMS Pharmaceutical Group's comprehensive portfolio, which includes branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialty pharmaceuticals such as oncology treatments, immunosuppressants, and emergency medications. As a critical regional prime vendor contractor under the PPV-G GEN V program, DMS Pharmaceutical Group has demonstrated substantial federal contracting activity and consistent performance across multiple therapeutic categories. The company's IDC, established on November 13, 2025, features a 30-month base period with three 30-month option periods extending through December 31, 2036, positioning the firm as an essential supplier for military medical system operations globally.
Quick answers
Who was awarded contract SPE2DX26FENTX?
SPE2DX26FENTX was awarded to DMS Pharmaceutical Group Inc. by Medical Supply Chain (Troop Support) on October 29, 2025.
How much is contract SPE2DX26FENTX worth?
The government has obligated $16,633 on SPE2DX26FENTX.
Is contract SPE2DX26FENTX an order under another contract?
Yes. SPE2DX26FENTX is a delivery order under SPE2DX16D9411, an indefinite delivery contract.
Was contract SPE2DX26FENTX competed?
The extent of competition for SPE2DX26FENTX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award